KAYNE RICHARD A 4
4 · Eiger BioPharmaceuticals, Inc. · Filed Nov 2, 2023
Insider Transaction Report
Form 4
KAYNE RICHARD A
10% Owner
Transactions
- Purchase
Common Stock
2023-11-02$0.30/sh+23,398$6,966→ 5,375,225 total(indirect: See footnote.) - Purchase
Common Stock
2023-10-31$0.26/sh+12,345$3,228→ 5,121,318 total(indirect: See footnote.) - Purchase
Common Stock
2023-10-31$0.24/sh+130,509$31,505→ 5,251,827 total(indirect: See footnote.) - Purchase
Common Stock
2023-11-01$0.28/sh+100,000$27,970→ 5,351,827 total(indirect: See footnote.) - Purchase
Common Stock
2023-10-31$0.26/sh+11,987$3,147→ 5,108,973 total(indirect: See footnote.)
Footnotes (3)
- [F1]Mr. Kayne shares control of Propel Bio Partners LLC, a Delaware limited liability company ("Propel General Partner"). Mr. Kayne and Propel General Partner act as the general partner of, or otherwise provide discretionary advisory services to, one or more private investment funds, and such investment funds acquired the referenced shares of Common Stock.
- [F2]Mr. Kayne is the trustee and beneficiary of the Richard Kayne and Suzanne Kayne Living Trust dtd 01/14/1999, a California trust (the "Family Trust"), and the Family Trust acquired the referenced shares of Common Stock.
- [F3]Mr. Kayne expressly disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of any pecuniary interest.